RemeGen Co., Ltd.

688331 · SSE

Public Market Listing

688331SSE

SSE primary exchange listing

Live quotes, historical charts, and market capitalization for RemeGen Co., Ltd. are available on Yahoo Finance.

View quote & market cap on Yahoo Finance ↗

External market data link · No third-party exchange redistribution

Assets

(6 total)
6Total Assets
0Approved
4Phase 3 / Filed
2Phase 1–2 / Early
10Diseases
Quick filter:
Showing 6 of 6 assets
Target & Modality
Phase 3
HER2Antibody–drug conjugate
Non-Small Cell Lung CancerBreast CancerGastric CancerBladder / Urothelial Cancer
HR+/HER2- Metastatic Breast Cancer, HER2-Positive Breast Cancer, Urothelial Carcinoma
Phase 3
PD-1 + VEGFMultispecific antibody
Non-Small Cell Lung Cancer
Phase 3
VEGF-A / FGF-2 (dual blockade)Protein / enzyme therapeutic
Age-Related Macular DegenerationDiabetic Macular Edema
Phase 3
BAFF / APRILProtein / enzyme therapeutic
Rheumatoid ArthritisIgA NephropathySjögren's DiseaseMyasthenia Gravis
Generalized Myasthenia Gravis
Phase 2
METAntibody–drug conjugate
Non-Small Cell Lung Cancer
Phase 1
IL-15 receptorProtein / enzyme therapeutic
Non-Small Cell Lung Cancer

Upcoming events

(24 total)

Estimated primary-completion dates from ClinicalTrials.gov and expected earnings reports. These are registry estimates, never confirmed readout dates; they can move as trials progress.

Add these trial readouts to your calendar: Apple or Outlook · Google Calendar · .ics link. The calendar updates when a registry date moves.

2026 (4)
December 2026 (4)
Disitamab VedotinPhase 2/3Gastric Cancer, Gastroesophageal Junction Adenocarcinoma
Est. primary completion 2026-12 · NCT06221748 · CT.gov ↗
What to watch
Disitamab VedotinPhase 2Urothelial Carcinoma
Est. primary completion 2026-12-11 · NCT04879329 · CT.gov ↗
What to watch
Disitamab VedotinPhase 3Urothelial Carcinoma, HER2-expressing
Est. primary completion 2026-12-31 · NCT05302284 · CT.gov ↗
What to watch
TelitaciceptPhase 3Myasthenia Gravis, Ocular
Est. primary completion 2026-12-31 · NCT07249632 · CT.gov ↗
What to watch
2027 (9)
January 2027 (1)
Disitamab VedotinPhase 3Urothelial Carcinoma
Est. primary completion 2027-01-29 · NCT05911295 · CT.gov ↗
What to watch
March 2027 (1)
TelitaciceptPhase 3Generalized Myasthenia Gravis
Est. primary completion 2027-03 · NCT06456580 · CT.gov ↗
What to watch
May 2027 (1)
RC148Phase 2/3Colorectal (Colon or Rectal) Cancer
Est. primary completion 2027-05-12 · NCT07462143 · CT.gov ↗
What to watch
June 2027 (1)
Disitamab VedotinPhase 2Cervical Cancer
Est. primary completion 2027-06-30 · NCT06155396 · CT.gov ↗
What to watch
October 2027 (1)
Disitamab VedotinPhase 1/2Breast Cancer, Breast Neoplasms
Est. primary completion 2027-10-25 · NCT06966453 · CT.gov ↗
What to watch
December 2027 (4)
RC148Phase 2Patients With Locally Advanced or Metastatic Non-Squamous NSCLC Requiring First-Line Treatment and no Driver Gene Alterations Confirmed by H …
Est. primary completion 2027-12 · NCT07874282 · CT.gov ↗
What to watch
Disitamab VedotinPhase 1/2Non-small Cell Lung Cancer
Est. primary completion 2027-12-01 · NCT05745740 · CT.gov ↗
What to watch
Disitamab VedotinPhase 3Breast Cancer
Est. primary completion 2027-12-31 · NCT04400695 · CT.gov ↗
What to watch
RC148Phase 3Non-Small Cell Lung Cancer
Est. primary completion 2027-12-31 · NCT07416474 · CT.gov ↗
What to watch
2028 (4)
May 2028 (1)
Disitamab VedotinPhase 3Gastric Carcinoma
Est. primary completion 2028-05-15 · NCT06944496 · CT.gov ↗
What to watch
July 2028 (1)
RC148Phase 2Patients With Unresectable Colorectal Cancer Requiring First-Line or Second-Line Therapy
Est. primary completion 2028-07 · NCT07895355 · CT.gov ↗
What to watch
December 2028 (2)
TelitaciceptPhase 3Primary Sjogren's Disease
Est. primary completion 2028-12 · NCT07404865 · CT.gov ↗
What to watch
RC28-EPhase 3Diabetic Macular Edema (DME), wAMD
Est. primary completion 2028-12-01 · NCT07936487 · CT.gov ↗
What to watch
2029 (5)
March 2029 (1)
Disitamab VedotinPhase 1/2High-risk Non-muscle Invasive Bladder Cancer
Est. primary completion 2029-03-15 · NCT06378242 · CT.gov ↗
What to watch
May 2029 (1)
TelitaciceptPhase 3CTD-ILD
Est. primary completion 2029-05-31 · NCT07495033 · CT.gov ↗
What to watch
June 2029 (1)
Disitamab VedotinPhase 3Gastric Carcinoma
Est. primary completion 2029-06-30 · NCT07315750 · CT.gov ↗
What to watch
July 2029 (1)
Disitamab VedotinPhase 2Breast Neoplasms, Gastroesophageal Junction Adenocarcinoma, HER2 Low Breast Neoplasms, HER2 Positive Breast Neoplasms, Stomach Neoplasms …
Est. primary completion 2029-07-28 · NCT06157892 · CT.gov ↗
What to watch
December 2029 (1)
RC148Phase 3Non-Small Cell Lung Cancer
Est. primary completion 2029-12 · NCT07756645 · CT.gov ↗
What to watch
2030 (1)
April 2030 (1)
RC148Phase 2/3Advanced Gastric or Gastroesophageal Junction Adenocarcinoma
Est. primary completion 2030-04-30 · NCT07935369 · CT.gov ↗
What to watch
2031 (1)
April 2031 (1)
RC148Phase 3Previously Untreated Locally Advanced (IIIB/IIIC) or Metastatic (IV) e Nsq NSCLC Without Actionable Genomic Alterations
Est. primary completion 2031-04 · NCT07829549 · CT.gov ↗
What to watch

See the full readout calendar ↗

Regulatory and conference events

(11)

Filings, regulator decisions, scientific presentations, topline results and licensing deals, each from a dated source. When a source gives only the month, the month is shown.

Recent

July 2026WithdrawalRC28-ERemeGen voluntarily withdraws the RC28-E DME application in China on NMPA review advice
China, NMPA · RemeGen Co., Ltd. · Source ↗
14 October 2025Topline resultTelitaciceptPhase III Sjögren's Syndrome trial meets primary endpoint
30 September 2025Topline resultRC28-EDME Phase 3 vs aflibercept (NCT05885503) met its primary endpoint
China · RemeGen Co., Ltd. and Santen Pharmaceutical Co., Ltd. · Source ↗
30 September 2025Filing acceptedRC28-EChina's CDE accepts the RC28-E BLA for diabetic macular edema
China, NMPA · RemeGen Co., Ltd. and Santen Pharmaceutical Co., Ltd. · Source ↗
19 September 2025Filing acceptedTelitaciceptChina BLA for Sjögren's Syndrome accepted by CDE
CN, NMPA · Source ↗
13 August 2025Topline resultTelitaciceptChina Phase 3 in primary Sjögren's (NCT05673993) met its primary endpoint
RemeGen Co., Ltd · Source ↗
27 May 2025ApprovalTelitaciceptTelitacicept approved in China for generalized myasthenia gravis
CN, NMPA · Source ↗
12 May 2025Topline resultDisitamab VedotinPhase 3 RC48-C016 meets PFS and OS primary endpoints
8 April 2025Topline resultTelitaciceptChina Phase 3 in generalized myasthenia gravis (NCT05737160): MG-ADL change -5.74 vs -0.91 with placebo at Week 24
RemeGen Co., Ltd · Source ↗
October 2024Filing acceptedDisitamab VedotinChina BLA accepted for DV in HER2-positive breast cancer with liver metastasis
CN, NMPA · Source ↗
October 2024Priority reviewDisitamab VedotinPriority review granted in China for DV in breast cancer with liver metastasis
CN, NMPA · Source ↗

Financial reports

Annual history (2 years)

PeriodRevenueR&DCash & equiv.Net loss / qtrFiling
2025-FY$451M$170M$213M—report ↗
View 1 more year
PeriodRevenueR&DCash & equiv.Net loss / qtrFiling
2024-FY$238M$214M—$205Mreport ↗